Note 3 - Revenue

12 Months Ended

Jun. 30, 2024

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

Note 3 - Revenue

The Company disaggregates its revenue into two segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys and Cotempla; and the Pediatric Portfolio, comprised of Karbinal, Poly-Vi-Flor and Tri-Vi-Flor. The Company completed its wind down of the Consumer Health Segment and entered into a definitive agreement to effect the Consumer Health Divestiture in the first quarter of fiscal 2025. The Consumer Health Segment was comprised of over ten consumer health products.

Revenues by Segment

Net revenue disaggregated by segment for the years ended June 30, 2024, and 2023, were as follows:

	Year Ended
	June 30,
	2024		2023
	(in thousands)
Rx Segment net revenue	$	65,183	$	73,799
Consumer Health Segment net revenue		15,819		33,600
Total net revenue	$	81,002	$	107,399

Revenues by Product Portfolio

Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended June 30, 2024, and 2023, were as follows:

	Year Ended
	June 30,
	2024		2023
	(in thousands)
ADHD Portfolio net revenue	$	57,784	$	46,855
Pediatric Portfolio net revenue		7,280		25,377
Other		119		1,567
Total Rx Segment net revenue	$	65,183	$	73,799

Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment was comprised of one product portfolio.

Revenues by Geographic Location

Net revenue disaggregated by geographic location as determined by the billing address of the Company’s customers for the years ended June 30, 2024, and 2023, were as follows:

	Year Ended
	June 30,
	2024		2023
	(in thousands)
United States net revenue	$	80,911	$	106,918
International net revenue		91		481
Total net revenue	$	81,002	$	107,399